NASDAQ · SUPN
Supernus Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for SUPN has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $0.57 | $0.57 | $0.57 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks- Fintel · Oct 30, 12:48 AM EDTSupernus Pharmaceuticals, Inc. Reports Record Third Quarter 2026 Revenues of $226.8 millionSupernus Pharmaceuticals, Inc. reported record total revenues of $226.8 million for the third quarter of 2026, representing an 18% increase compared to the same period in 2025. This growth was driven by combined revenues of the Company's four growth products, which increased to $
- Zacks · Oct 29, 6:05 PM EDTSupernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue EstimatesSupernus (SUPN) delivered earnings and revenue surprises of +89.80% and +1.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 28, 12:11 PM EDTBIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View TightenedBiogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.
- Zacks · Oct 26, 8:38 AM EDTBiogen Q3 Preview: Will Growth Products Drive an Earnings Beat?Biogen heads into Q3 earnings with growth from new drugs and acquisitions potentially offsetting declining multiple sclerosis sales.
- Zacks · Oct 22, 9:00 AM EDTEarnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to DeclineSupernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Fintel · Oct 22, 8:22 AM EDTSupernus Pharmaceuticals Announces FDA Recognition of Seven Years of Orphan-Drug Exclusivity for ONAPGOSupernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that the U.S. Food and Drug Administration has recognized seven years of orphan-drug exclusive appr
- Zacks · Sep 28, 9:41 AM EDTCan Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.
- Zacks · Aug 24, 5:45 PM EDTIs the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?Investors need to pay close attention to SUPN stock based on the movements in the options market lately.
- Zacks · Aug 21, 12:40 PM EDTIndivior's Supernus Merger Could Broaden Its Growth Engine in 2026INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.
- Zacks · Aug 21, 10:48 AM EDTShould Investors Buy INDV as Sublocade Growth Meets Rising Risks?Indivior's Sublocade growth and cost cuts are lifting earnings and cash flow, but pipeline setbacks, legal risks and valuation add caution.
- Zacks · Aug 20, 10:12 AM EDTShould You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
- Zacks · Aug 7, 11:40 AM EDTSUPN vs. TEVA: Which Stock Should Value Investors Buy Now?SUPN vs. TEVA: Which Stock Is the Better Value Option?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Supernus Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.